<p>Burney Co. 在第三季度收购了 Qiagen N.V.（纽约证券交易所代码：QGEN - 免费报告）的新股份，根据其最近向证券交易委员会（SEC）的披露，该基金收购了 38,699 股公司股票，价值约为 1,729,000 美元。</p>
<ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p>其他大型投资者最近也调整了对该公司的持股。MAI Capital Management 在第二季度将其在 Qiagen 的持股增加了 998.9%。MAI Capital Management 目前拥有 978 股公司股票，价值 47,000 美元，在此期间又购买了 889 股。Farther Finance Advisors LLC 在第二季度将其在 Qiagen 的持股增加了 400.5%。Farther Finance Advisors LLC 目前拥有 1,061 股公司股票，价值 51,000 美元，在上个季度又收购了 849 股。Allworth Financial LP 在第二季度将其在 Qiagen 的持股增加了 260.1%。Allworth Financial LP 目前拥有 1,102 股公司股票，价值 53,000 美元，在上个季度又收购了 796 股。GAMMA Investing LLC 在第三季度将其在 Qiagen 的持股增加了 375.5%。GAMMA Investing LLC 目前拥有 1,241 股公司股票，价值 55,000 美元，在此期间又收购了 980 股。最后，Cullen Frost Bankers Inc. 在第二季度将其在 Qiagen 的持股增加了 13,144.4%。Cullen Frost Bankers Inc. 目前拥有 1,192 股公司股票，价值 57,000 美元，在上个季度又购买了 1,183 股。70.00% 的股票由机构投资者持有。</p>
<h2>Qiagen 股票表现</h2>
<p>纽约证券交易所代码：QGEN 周一开盘价为 45.30 美元。该股票的 50 日移动平均价格为 46.10 美元，200 日移动平均价格为 47.11 美元。该公司的市值为 100.7 亿美元，市盈率为 24.62，PEG 比率为 2.32，贝塔值为 0.67。该公司的债务与股本比率为 0.45，速动比率为 2.30，流动比率为 2.60。Qiagen N.V. 的 52 周低点为 37.63 美元，52 周高点为 51.88 美元。</p>
<p>Qiagen 的股票计划在 1 月 8 日（星期四）早晨进行反向拆分。19-20 的反向拆分最近已被宣布。股东持有的股份数量将在 1 月 7 日（星期三）收盘后进行调整。</p>
<p>Qiagen（纽约证券交易所代码：QGEN - 获取免费报告）最近于 11 月 6 日（星期四）发布了其财报。该公司报告本季度每股收益为 0.61 美元，超出市场共识预期的 0.58 美元，超出 0.03 美元。该公司本季度的收入为 5.3258 亿美元，而分析师预期为 5.2568 亿美元。Qiagen 的净利润率为 19.58%，股本回报率为 14.80%。该公司的季度收入较去年同期增长了 6.2%。去年同期，该公司每股收益为 0.57 美元。整体来看，股票分析师预计 Qiagen N.V. 本财年将发布 2.26 美元的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对该公司发表了看法。Wall Street Zen 在 12 月 21 日（星期日）的报告中将 Qiagen 的评级从 “持有” 上调至 “买入”。花旗集团在 12 月 11 日（星期四）的研究报告中将 Qiagen 的评级从 “买入” 下调至 “中性”，并将其股票目标价从 55.00 美元下调至 50.00 美元。Weiss Ratings 在 12 月 22 日（星期一）的研究报告中重新发布了对 Qiagen 股票的 “持有（c）” 评级。最后，巴克莱在 12 月 15 日（星期一）的研究报告中重申了 “增持” 评级，并将 Qiagen 股票的目标价从 53.00 美元上调至 55.00 美元。两位股票研究分析师对该股票给予了买入评级，八位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 49.61 美元。</p>
<p><strong>阅读我们最新的 QGEN 股票报告</strong></p>
<h2>Qiagen 公司简介</h2>
<p>（免费报告）</p>
<p>Qiagen NV（纽约证券交易所代码：QGEN）是一家全球样本和检测技术提供商，旨在支持分子诊断、应用测试、学术研究和制药开发领域的分子检测。该公司的解决方案涵盖了核酸和蛋白质分析的完整工作流程，为客户提供标准化的试剂盒、仪器和软件工具，以简化 DNA、RNA 和蛋白质的准备、检测和定量。</p>
<p>该公司的产品组合包括核酸提取和纯化系统、聚合酶链反应（PCR）试剂和仪器、数字 PCR 平台、下一代测序（NGS）文库准备试剂盒和蛋白质组学解决方案。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Qiagen</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><strong>想看看其他对 QGEN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Qiagen N.V.（纽约证券交易所代码：QGEN - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0V_U3ltYm9sPVFHRU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0V_U3ltYm9sPVFHRU4"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Qiagen 吗？</h2>
<p>在考虑 Qiagen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Qiagen 并不在名单上。</p>
<p>虽然 Qiagen 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

快而精医药

<p>Burney Co. 在第三季度收购了 38,699 股快而精医药（NYSE:QGEN），价值约 173 万美元，已向 SEC 披露。其他投资者，包括 MAI Capital Management 和 Farther Finance Advisors，也显著增加了在快而精医药的持股。该股票目前交易价格为 45.30 美元，市值为 100.7 亿美元。快而精医药最近报告的每股收益为 0.61 美元，超出预期。分析师对该股票的评级不一，平均目标价格为 49.61 美元</p>

<p>Burney Co. acquired a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 38,699 shares of the company's stock, valued at approximately $1,729,000.</p>
<div class="lb-trans"><p>Burney Co. 在第三季度收购了 Qiagen N.V.（纽约证券交易所代码：QGEN - 免费报告）的新股份，根据其最近向证券交易委员会（SEC）的披露，该基金收购了 38,699 股公司股票，价值约为 1,729,000 美元。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p>Other large investors also recently modified their holdings of the company. MAI Capital Management boosted its holdings in shares of Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company's stock worth $47,000 after buying an additional 889 shares during the period. Farther Finance Advisors LLC lifted its position in Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after acquiring an additional 849 shares during the last quarter. Allworth Financial LP lifted its position in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company's stock worth $53,000 after acquiring an additional 796 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Qiagen by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company's stock worth $55,000 after acquiring an additional 980 shares during the period. Finally, Cullen Frost Bankers Inc. grew its position in shares of Qiagen by 13,144.4% in the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company's stock valued at $57,000 after purchasing an additional 1,183 shares during the last quarter. 70.00% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。MAI Capital Management 在第二季度将其在 Qiagen 的持股增加了 998.9%。MAI Capital Management 目前拥有 978 股公司股票，价值 47,000 美元，在此期间又购买了 889 股。Farther Finance Advisors LLC 在第二季度将其在 Qiagen 的持股增加了 400.5%。Farther Finance Advisors LLC 目前拥有 1,061 股公司股票，价值 51,000 美元，在上个季度又收购了 849 股。Allworth Financial LP 在第二季度将其在 Qiagen 的持股增加了 260.1%。Allworth Financial LP 目前拥有 1,102 股公司股票，价值 53,000 美元，在上个季度又收购了 796 股。GAMMA Investing LLC 在第三季度将其在 Qiagen 的持股增加了 375.5%。GAMMA Investing LLC 目前拥有 1,241 股公司股票，价值 55,000 美元，在此期间又收购了 980 股。最后，Cullen Frost Bankers Inc. 在第二季度将其在 Qiagen 的持股增加了 13,144.4%。Cullen Frost Bankers Inc. 目前拥有 1,192 股公司股票，价值 57,000 美元，在上个季度又购买了 1,183 股。70.00% 的股票由机构投资者持有。</p>
</div><h2>Qiagen Stock Performance</h2>
<div class="lb-trans"><h2>Qiagen 股票表现</h2>
</div><p>NYSE:QGEN opened at $45.30 on Monday. The stock has a fifty day moving average price of $46.10 and a 200-day moving average price of $47.11. The company has a market cap of $10.07 billion, a price-to-earnings ratio of 24.62, a PEG ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen N.V. has a fifty-two week low of $37.63 and a fifty-two week high of $51.88.</p>
<div class="lb-trans"><p>纽约证券交易所代码：QGEN 周一开盘价为 45.30 美元。该股票的 50 日移动平均价格为 46.10 美元，200 日移动平均价格为 47.11 美元。该公司的市值为 100.7 亿美元，市盈率为 24.62，PEG 比率为 2.32，贝塔值为 0.67。该公司的债务与股本比率为 0.45，速动比率为 2.30，流动比率为 2.60。Qiagen N.V. 的 52 周低点为 37.63 美元，52 周高点为 51.88 美元。</p>
</div><p>Qiagen's stock is scheduled to reverse split on the morning of Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.</p>
<div class="lb-trans"><p>Qiagen 的股票计划在 1 月 8 日（星期四）早晨进行反向拆分。19-20 的反向拆分最近已被宣布。股东持有的股份数量将在 1 月 7 日（星期三）收盘后进行调整。</p>
</div><p>Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.57 EPS. As a group, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Qiagen（纽约证券交易所代码：QGEN - 获取免费报告）最近于 11 月 6 日（星期四）发布了其财报。该公司报告本季度每股收益为 0.61 美元，超出市场共识预期的 0.58 美元，超出 0.03 美元。该公司本季度的收入为 5.3258 亿美元，而分析师预期为 5.2568 亿美元。Qiagen 的净利润率为 19.58%，股本回报率为 14.80%。该公司的季度收入较去年同期增长了 6.2%。去年同期，该公司每股收益为 0.57 美元。整体来看，股票分析师预计 Qiagen N.V. 本财年将发布 2.26 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts recently weighed in on the company. Wall Street Zen raised Qiagen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Sunday, December 21st. Citigroup cut Qiagen from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their price objective for the stock from $55.00 to $50.00 in a research report on Thursday, December 11th. Weiss Ratings reissued a &#34;hold (c)&#34; rating on shares of Qiagen in a research report on Monday, December 22nd. Finally, Barclays restated an &#34;overweight&#34; rating and issued a $55.00 price target (up from $53.00) on shares of Qiagen in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and an average price target of $49.61.</p>
<div class="lb-trans"><p>几位分析师最近对该公司发表了看法。Wall Street Zen 在 12 月 21 日（星期日）的报告中将 Qiagen 的评级从 “持有” 上调至 “买入”。花旗集团在 12 月 11 日（星期四）的研究报告中将 Qiagen 的评级从 “买入” 下调至 “中性”，并将其股票目标价从 55.00 美元下调至 50.00 美元。Weiss Ratings 在 12 月 22 日（星期一）的研究报告中重新发布了对 Qiagen 股票的 “持有（c）” 评级。最后，巴克莱在 12 月 15 日（星期一）的研究报告中重申了 “增持” 评级，并将 Qiagen 股票的目标价从 53.00 美元上调至 55.00 美元。两位股票研究分析师对该股票给予了买入评级，八位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 49.61 美元。</p>
</div><p><strong>Read Our Latest Stock Report on QGEN</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 QGEN 股票报告</strong></p>
</div><h2>Qiagen Company Profile</h2>
<div class="lb-trans"><h2>Qiagen 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.</p>
<div class="lb-trans"><p>Qiagen NV（纽约证券交易所代码：QGEN）是一家全球样本和检测技术提供商，旨在支持分子诊断、应用测试、学术研究和制药开发领域的分子检测。该公司的解决方案涵盖了核酸和蛋白质分析的完整工作流程，为客户提供标准化的试剂盒、仪器和软件工具，以简化 DNA、RNA 和蛋白质的准备、检测和定量。</p>
</div><p>The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.</p>
<div class="lb-trans"><p>该公司的产品组合包括核酸提取和纯化系统、聚合酶链反应（PCR）试剂和仪器、数字 PCR 平台、下一代测序（NGS）文库准备试剂盒和蛋白质组学解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Qiagen</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Qiagen</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元 AI 奇迹股票” 即将腾飞</li>
<li>100 万美元在退休中能维持多久？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding QGEN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 QGEN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Qiagen N.V.（纽约证券交易所代码：QGEN - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVFHRU4" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=QGEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Qiagen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Qiagen 吗？</h2>
</div><p>Before you consider Qiagen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Qiagen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Qiagen 并不在名单上。</p>
</div><p>While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Qiagen 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Burney Co. 购入了 38,699 股快而精医药 $QGEN